Myosin Light Chain Kinase Inhibitor Compounds, Compositions and Related Methods of Use

Keyphrases

• Kinase Inhibitor 100%
• Myosin Light Chain Kinase 100%
• Inhibitor Compound 100%
• Method of Use 100%
• Compound Composition 100%
• Sepsis 50%
• Tissue Barrier 50%
• Tissue Injury 50%
• Natural Deep Eutectic Solvents (NADES) 50%
• Therapeutic Candidates 50%
• Vascular Leakage 50%
• Potential Therapeutics 25%
• Protein Kinase 25%
• Lung Injury 25%
• Unmet 25%
• Multiple Organ Failure 25%
• Calmodulin 25%
• Small Molecule Therapeutics 25%
• Molecular Properties 25%
• Small Molecule Inhibitors 25%
• Endotoxin 25%
• Acute Lung Injury 25%
• Bioavailable 25%
• Barrier Dysfunction 25%
• Crohn's Disease 25%
• US Patents 25%
• Vascular Leak 25%
• Lung Disorders 25%
• Effective Rate of Protection 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Tissue Injury 100%
• Myosin Light Chain Kinase 100%
• Myosin Light Chain Kinase Inhibitor 100%
• Sepsis 100%
• Acute Lung Injury 50%
• Multiple Organ Failure 50%
• Lung Disease 50%
• Lead Compound 50%
• Endotoxin 50%
• Edoxudine 50%
• Protein Kinases 50%
• Bioavailability 50%
• Crohn's Disease 50%
• Calmodulin 50%
• Diseases 50%